GlobalRPH - Arthritis News

Medical News

< back to feeds
Arthritis News (Page 10)
Childhood Arthritis: Common But Preventable Consequence Of Lyme Disease When left untreated, children infected with Lyme disease can experience many severe complications as a result including arthritis, problems with the heart or central nervous system. Lyme disease in children is often overlooked in its earliest stages, leading to these complications later on, according to Emma Jane MacDermott, M.D., pediatric rheumatologist at Hospital for Special Surgery in New York. ...more	04 July 2009
Nearly Half Of Rheumatoid Arthritis Sufferers Feel Early Treatment Would Have Given Them More Independence A UK survey of 575 rheumatoid arthritis sufferers highlights the importance of maintaining independence and the significant impact that early diagnosis and treatment can have. Over 94% of those surveyed claimed that their independence was compromised in some way, with over 60% saying it was compromised significantly. ...more	03 July 2009
MorphoSys And The University Of Melbourne File New Patent Applications In MOR103 Program MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and the University of Melbourne announced today an agreement to cooperate on investigating new therapeutic applications for MorphoSys's MOR103 program. MOR103, a HuCAL antibody against human GM-CSF (Granulocyte macrophage-colony stimulating factor), is currently in development for the treatment of rheumatoid arthritis (RA). ...more	02 July 2009
POZEN Submits New Drug Application For VIMOVO™ (PN 400) POZEN Inc. (NASDAQ:POZN), announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the marketing approval of VIMOVO™ (PN 400), the combination of enteric coated (EC) naproxen and immediate release esomeprazole. POZEN and AstraZeneca entered into a global co-development agreement for VIMOVO in August 2006. ...more	02 July 2009
Study Provides Greater Understanding Of Lyme Disease-Causing Bacteria Lyme disease in the U.S. is caused by the tick-borne bacteria Borrelia burgdorferi and usually begins with a skin lesion, after which the bacteria spread throughout the body to the nervous system, heart or joints. About 60 percent of untreated individuals develop arthritis, which affects the knees in particular. ...more	02 July 2009
Examining The Risk Of Tuberculosis From Arthritis Medication Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment. ...more	02 July 2009
Aclasta(R) (zoledronic Acid 5mg) Approved In EU To Treat Steroid Induced Osteoporosis In Men And Post-menopausal Women Aclasta® (zoledronic acid 5 mg)[1] has been approved in the European Union to treat men and post-menopausal women with osteoporosis caused by the long-term use of glucocorticoids, commonly known as steroids. ...more	02 July 2009
Extending The Shelf Life Of Antibody Drugs A new computer model developed at MIT can help solve a problem that has plagued drug companies trying to develop promising new treatments made of antibodies: Such drugs have a relatively short shelf life because they tend to clump together, rendering them ineffective. Antibodies are the most rapidly growing class of human drugs, with the potential to treat cancer, arthritis and other chronic inflammatory and infectious diseases. ...more	01 July 2009
Better Classification And Treatment Of Juvenile Arthritis Via Gene Expression Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). Eventually such findings could enable doctors to target more aggressive treatment to children at risk of more severe arthritis, while those likely to have milder disease could be spared the stronger treatments that carry a greater risk of side effects. ...more	01 July 2009
Discovery Of New Trigger For Chronic Inflammation In Rheumatoid Arthritis A signal molecule made by the human body that triggers the immune system into action may be important in rheumatoid arthritis, according to new research published in Nature Medicine. The authors of the study, from Imperial College London, say that if scientists could block this signal, it may be possible to develop more effective arthritis treatments. Rheumatoid arthritis is the most common autoimmune disease, affecting around 1 in 100 people. ...more	29 June 2009
Patients With Rheumatoid Arthritis Who Had Poor Response To Other Drugs Could Have Better Results With Golimumab An article published Online First and in this week's edition of reports information about Golimumab, a new tumour necrosis factor-Î± (TNF-Î±) inhibitor. It reduces the signs and symptoms of rheumatoid arthritis in patients who have previously received any other TNF-Î± inhibitor. This drug might be a good alternative for patients who have inadequate responses to one or two other TNF-Î± inhibitors. Over three million people in Europe and about 1. ...more	29 June 2009
Arthritis Drug Shows Promise In Clinical Trial A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective. Researchers writing in BioMed Central's open access journal Arthritis Research and Therapy have shown that treatment with masitinib significantly reduced the severity of active arthritis. ...more	29 June 2009
Cimzia(R), The Only PEGylated Anti-TNF, Recommended For Approval In The EU For Rheumatoid Arthritis UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for Cimzia® (certolizumab pegol), in combination with methotrexate (MTX), for the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX, has been inadequate. ...more	27 June 2009
Total Knee Replacements Increase Mobility And Motor Skills In Older Patients According to a new study from researchers at Duke University, total knee arthroplasty (TKA) procedures performed in older patients with osteoarthritis of the knee result in long-term, significant improvement of physical functioning and motor skills when compared to patients who do not receive TKA. ...more	27 June 2009
MorphoSys Reports Filing For Phase 1b/2a Trial For Its Lead Program MOR103 In Rheumatoid Arthritis MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the Company has submitted an application for the authorization of a phase 1b/2a clinical study in patients with active rheumatoid arthritis (RA) for its lead drug MOR103, a fully human HuCAL-derived monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor. ...more	25 June 2009
New 18 Week Arthritis Commissioning Pathway, UK The Rheumatology Futures Project and the Department of Health have launched a new 18-week commissioning pathway for inflammatory arthritis (IA). ...more	25 June 2009
Flexcin With CM8TM Provides Arthritis And Joint Pain Remedy According to the CDC, 46 million Americans were told by a doctor they have arthritis, the leading cause of disability in the United States. Flexcin International, Inc., a natural supplement company offering the only joint pain remedy products with CM8™, offers arthritis and bursitis treatment for anyone suffering from pain-related disease and injuries. ...more	24 June 2009
NÃ©ovacs To Expand Clinical Testing Of Its TNF-alpha Kinoid Lead Product Candidate Following Positive Preliminary Findings From A Phase I/II Study Neovacs, a biotechnology company developing proprietary immunotherapeutics for autoimmune and chronic diseases, announced that subject to regulatory consent, it plans to initiate a Phase II study of its TNF-alpha Kinoid later this year in rheumatoid arthritis patients who have failed treatment with at least one TNF-alpha inhibitor. The decision to proceed with the trial was based on an initial review of encouraging data from the company's Phase I/II study in Crohn's disease. ...more	23 June 2009
Disclosing Your Feelings May Help The Course Of Rheumatoid Arthritis: Results From A Randomized Clinical Trial The health and physiological effects of an intervention which facilitates the opening of feelings are described in a paper published in the current issue of Psychotherapy and Psychosomatics. The efficacy of emotional disclosure in alleviating psychological and physical stress has been well documented in controlled laboratory studies. A next step is to evaluate its clinical utility in 'real world' settings. ...more	18 June 2009
Structures From Immune System's Oldest Branch Shed Light On A Range Of Diseases How molecules of the oldest branch of the human immune system have interconnected has remained a mystery. Now, two new structures, both involving a central component of an enzyme important to the complement system of the immune response, reveal how this system fights invading microbes while avoiding problems of the body attacking itself. ...more	18 June 2009
Pages of Results: [First Page] [Prev] 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 [Next] [Last Page]
Arthritis News courtesy of Medical News Today	back to top

Medical News

Looking for a Job?

Career Center

Popular Tools

Disclaimer Contact Us Privacy Policy Website Search	We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc.